| First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ J Niu, C Maurice-Dror, DH Lee, DW Kim, A Nagrial, M Voskoboynik, ... Annals of Oncology 33 (2), 169-180, 2022 | 140 | 2022 |
| First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in … R Geva, M Voskoboynik, K Dobrenkov, K Mayawala, J Gwo, R Wnek, ... Cancer 126 (22), 4926-4935, 2020 | 45 | 2020 |
| Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. HT Arkenau, JC Sachdev, MM Mita, R Dziadziuszko, CC Lin, JCH Yang, ... Journal of Clinical Oncology 33 (15_suppl), 8063-8063, 2015 | 31 | 2015 |
| Combination Therapies For The Treatment Of Advanced Melanoma–A Review Of Current Evidence M Voskoboynik, HT Arkenau | 31 | 2014 |
| A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia JD Lickliter, HK Gan, M Voskoboynik, S Arulananda, B Gao, A Nagrial, ... Drug design, development and therapy, 1177-1189, 2020 | 27 | 2020 |
| Prospective analysis of 895 patients on a UK Genomics Review Board DA Moore, M Kushnir, G Mak, H Winter, T Curiel, M Voskoboynik, ... ESMO open 4 (2), e000469, 2019 | 27 | 2019 |
| 1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC J Niu, A Nagrial, M Voskoboynik, HC Chung, DH Lee, MJ Ahn, TM Bauer, ... Annals of Oncology 31, S891-S892, 2020 | 24 | 2020 |
| SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting A Greystoke, N Steele, HT Arkenau, F Blackhall, N Md Haris, CR Lindsay, ... British Journal of Cancer 117 (7), 938-946, 2017 | 23 | 2017 |
| Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer J Hilton, MC Cristea, M Voskoboynik, S Postel-Vinay, W Edenfield, ... Annals of Oncology 29, viii134, 2018 | 18 | 2018 |
| A phase I/II study to assess the safety and efficacy of pazopanib and pembrolizumab combination therapy in patients with advanced renal cell carcinoma S Chowdhury, JR Infante, R Hawkins, MH Voss, R Perini, T Arkenau, ... Clinical genitourinary cancer 19 (5), 434-446, 2021 | 17 | 2021 |
| Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors J Lickliter, L Mileshkin, M Voskoboynik, M Millward, A Freimund, ... Annals of Oncology 28, v123, 2017 | 17 | 2017 |
| A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen … S Chowdhury, HA Burris, M Patel, JR Infante, SF Jones, M Voskoboynik, ... European Journal of Cancer 1 (69), S145, 2016 | 17 | 2016 |
| An update on adjuvant systemic therapies in melanoma E Samuel, M Moore, M Voskoboynik, M Shackleton, A Haydon Melanoma Management 6 (3), MMT28, 2019 | 16 | 2019 |
| First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with … R Geva, M Voskoboynik, AM Beebe, J Gwo, K Dobrenkov, E Chartash, ... Journal of Clinical Oncology 36 (15_suppl), 3029-3029, 2018 | 16 | 2018 |
| Clinicopathological characteristics associated with BRAFK601E and BRAFL597 mutations in melanoma M Voskoboynik, V Mar, S Mailer, A Colebatch, A Fennessy, A Logan, ... Pigment cell & melanoma research 29 (2), 222-228, 2016 | 16 | 2016 |
| Impact of radiotherapy on the efficacy and toxicity of anti-PD-1 inhibitors in metastatic NSCLC E Samuel, G Lie, A Balasubramanian, A Hiong, Y So, M Voskoboynik, ... Clinical lung cancer 22 (3), e425-e430, 2021 | 15 | 2021 |
| Stereotactic radiation therapy combined with immunotherapy against metastatic melanoma: long-term results of a phase 1 clinical trial G Ratnayake, S Reinwald, M Shackleton, M Moore, M Voskoboynik, ... International Journal of Radiation Oncology* Biology* Physics 108 (1), 150-156, 2020 | 15 | 2020 |
| BMS-986158, a small molecule inhibitor of the bromodomain and extraterminal domain proteins, in patients with selected advanced solid tumors: results from a phase 1/2a trial J Hilton, M Cristea, S Postel-Vinay, C Baldini, M Voskoboynik, ... Cancers 14 (17), 4079, 2022 | 14 | 2022 |
| Correction to: 33rd annual meeting & pre-conference programs of the society for immunotherapy of cancer (SITC 2018) S Berry, N Giraldo, P Nguyen, B Green, H Xu, A Ogurtsova, A Soni, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 12 | 2019 |
| High‐dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients J Lewin, M Dickinson, M Voskoboynik, M Collins, D Ritchie, G Toner Internal Medicine Journal 44 (8), 771-778, 2014 | 12 | 2014 |
